


# Establishing a human iPSC-derived neuron model of *SLC35A2*- associated epilepsy

\*Lai D<sup>1</sup>, Williams D<sup>2</sup>, Sosicka P<sup>3</sup>, Ressler AK<sup>2</sup>, Freeze HH<sup>3</sup>, Boland MJ, EL Heinzen<sup>1</sup>.

<sup>1</sup>University of North Carolina, Chapel Hill, NC; <sup>2</sup>Columbia University, New York, NY; <sup>3</sup>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA

# *SLC35A2* (Solute carrier 35)


- Gene → Xp11.23
- Protein → UDP-galactose transporter (UGT2)
- Function → transports UDP-galactose from cytosol to Golgi lumen where it is used for the galactosylation of N-glycosylated proteins




# *SLC35A2* and human disorders

- Congenital disorder of glycosylation
- X-linked developmental and epileptic encephalopathy
- Intractable neocortical epilepsy


# Approach




# *SLC35A2* CRISPR edited iPSCs retain pluripotent characteristics




# *SLC35A2* variants encode LOF proteins resulting in reduced sialylated N-linked glycans



# Experimental Timeline



# *SLC35A2* variant harboring neurons are hypoactive and generate asynchronous networks



\*Days *in vitro* refers to the number of days plated on MEA from papain dissociation



ESHELMAN SCHOOL  
OF PHARMACY



COLUMBIA UNIVERSITY  
INSTITUTE FOR  
GENOMIC MEDICINE



Sanford Burnham Prebys  
MEDICAL DISCOVERY INSTITUTE




Erin Heinzen, PharmD, PhD



Michael Boland, PhD



Hudson Freeze, PhD



Dulcie Lai, PharmD, PhD



Meethila Gade, MSc



Damian Williams, PhD



Paulina Sosicka, PhD



National Institute of  
Neurological Disorders  
and Stroke